文献速递炎症性肠病

英夫利西单抗谷浓度较高与克罗恩病患者肛周瘘管愈合相关

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-02-17

这项横断面研究纳入117例接受英夫利西单抗治疗至少24周的克罗恩病肛周瘘管患者,发现瘘管愈合者的中位血清英夫利西单抗谷浓度显著高于活动性瘘管者(15.8 vs 4.4 μg/mL,P < 0.0001),且抗英夫利西单抗抗体与瘘管愈合几率降低相关(OR: 0.04)。作者认为达到英夫利西单抗水平≥10.1 mcg/mL可能作为达标治疗策略的一部分改善结局。

要点

  • 瘘管愈合者中位英夫利西单抗谷浓度15.8 μg/mL,活动性瘘管者4.4 μg/mL(P < 0.0001)。
  • 英夫利西单抗水平与瘘管愈合关联的AUC为0.82(P < 0.0001)。
  • 有抗英夫利西单抗抗体者瘘管愈合几率降低(OR: 0.04,95%CI: 0.005-0.3,P < 0.001)。

核心结论

  • 血清英夫利西单抗水平与瘘管愈合率之间存在显著关联。
  • 作者认为,在克罗恩病肛周瘘管患者中达到英夫利西单抗水平≥10.1 mcg/mL可能作为达标治疗策略的一部分改善结局。

研究设计与样本

  • 横断面研究,纳入接受英夫利西单抗治疗至少24周的克罗恩病肛周瘘管患者117例。
  • 排除接受粪便转流手术或直肠切除术的患者。
  • 预测变量包括人口学特征、疾病表型、疾病活动度、英夫利西单抗水平、抗英夫利西单抗抗体。
  • 主要结局为瘘管愈合,定义为无引流;次要结局为瘘管完全闭合和黏膜愈合。

主要发现

  • 瘘管愈合患者的中位血清英夫利西单抗水平显著高于活动性瘘管患者(15.8 vs 4.4 μg/mL,P < 0.0001)。
  • 英夫利西单抗水平越高,瘘管愈合有递增性获益。
  • 瘘管愈合与英夫利西单抗水平关联的AUC为0.82(P < 0.0001)。
  • 英夫利西单抗水平与瘘管闭合关联的AUC为0.69(P = 0.014)。
  • 有抗英夫利西单抗抗体的患者实现瘘管愈合的几率更低(OR: 0.04 [95%CI: 0.005-0.3],P < 0.001)。

关键数值与推荐

  • 瘘管愈合者中位英夫利西单抗谷浓度15.8 μg/mL vs 活动性瘘管者4.4 μg/mL(P < 0.0001)。
  • 瘘管愈合与英夫利西单抗水平关联的AUC为0.82(P < 0.0001)。
  • 瘘管闭合与英夫利西单抗水平关联的AUC为0.69(P = 0.014)。
  • 抗英夫利西单抗抗体与瘘管愈合的OR为0.04(95%CI: 0.005-0.3,P < 0.001)。
  • 作者提出英夫利西单抗水平≥10.1 mcg/mL可能改善结局。

临床怎么用

  • 作者认为,在克罗恩病肛周瘘管患者中达到英夫利西单抗水平≥10.1 mcg/mL可能作为达标治疗策略的一部分改善结局。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some patients do not benefit from therapy. AIM: To assess the correlation between perianal fistula healing and trough levels of infliximab. METHODS: In this cross-sectional study, we identified patients with Crohn's disease who had perianal fistulas and were treated with infliximab for at least 24 weeks. We excluded patients who underwent a faecal diversion procedure or proctectomy. Predictive variables included demographics, disease phenotype, disease activity, infliximab levels, anti-infliximab antibodies. The primary outcome was fistula healing defined as the absence of drainage. The secondary outcome was complete fistula closure and mucosal healing. RESULTS: 117 patients were included. Patients with fistula healing had significantly higher median serum infliximab levels when compared to those with active fistulas [15.8 vs. 4.4 μg/mL, respectively (P < 0.0001)]. There was an incremental gain in fistula healing with higher infliximab levels. The AUC for the association between fistula healing and infliximab levels was 0.82 (P < 0.0001), while the AUC for the association of infliximab levels and fistula closure was 0.69 (P = 0.014). Patients with anti-infliximab antibodies had a lower chance of achieving fistula healing (OR: 0.04 [95%CI: 0.005-0.3], P < 0.001). CONCLUSIONS: There is a significant association between serum infliximab levels and rates of fistula healing. Achieving infliximab levels ≥10.1 mcg/mL in patients with Crohn's disease and perianal fistulas may improve outcomes as part of a treat-to-target strategy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther. 2017. PMID: 28211593. doi:10.1111/apt.13970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。